APIMEDS PHARMACEUTICALS US, INC. Foreign Currency Transaction Gain (Loss), before Tax
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Foreign Currency Transaction Gain (Loss), before Tax of $458 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $458.00.
- APIMEDS PHARMACEUTICALS US, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$1.57K.
- APIMEDS PHARMACEUTICALS US, INC. foreign currency transaction gain (loss), before tax for fiscal 2025 was -$521.00.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|
| 2026-06-30 | $458.00 10-Q · filed 2026-08-14 | -$1.11K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$1.57K 10-Q · filed 2026-05-26 | ||
| 2025-12-31 | -$521.00 10-K · filed 2026-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |